These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 3579262)

  • 1. Bowel flora changes in humans receiving cefixime (CL 284,635) or cefaclor.
    Finegold SM; Ingram-Drake L; Gee R; Reinhardt J; Edelstein MA; MacDonald K; Wexler H
    Antimicrob Agents Chemother; 1987 Mar; 31(3):443-6. PubMed ID: 3579262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative activity of cefixime and cefaclor in an in vitro model simulating human pharmacokinetics.
    Nies BA
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):558-61. PubMed ID: 2504600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of cefixime versus cefaclor in respiratory tract infections.
    Dorow P
    J Chemother; 1989 Aug; 1(4):257-60. PubMed ID: 2809693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
    Fuchs PC; Jones RN; Barry AL; Thornsberry C; Ayers LW; Gavan TL; Gerlach EH
    Diagn Microbiol Infect Dis; 1986 Jul; 5(2):151-62. PubMed ID: 3522088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of a new broad spectrum, beta-lactamase-stable oral cephalosporin, cefixime.
    Neu HC
    Pediatr Infect Dis J; 1987 Oct; 6(10):958-62. PubMed ID: 3696836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of S6472 and cefaclor on bacterial flora in adult human feces].
    Motohiro T; Aramaki M; Tanaka K; Koga T; Shimada Y; Tomita S; Sakata Y; Fujimoto T; Nishiyama T; Kuda N
    Jpn J Antibiot; 1986 Jan; 39(1):177-246. PubMed ID: 3702058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effects of cefixime and cefaclor on pharyngeal flora in children].
    Sakata H; Maruyama S
    Kansenshogaku Zasshi; 1991 May; 65(5):546-51. PubMed ID: 1880444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Double-blind comparison of cefixime and cefaclor in the treatment of acute otitis media in children.
    Piippo T; Stefansson S; Pitkäjärvi T; Lundberg C
    Scand J Infect Dis; 1991; 23(4):459-65. PubMed ID: 1957129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of the administration of cefixime on aerobic fecal flora in children].
    Borderon JC; Bremond M; Laugier J; Despert F
    Pathol Biol (Paris); 1992 May; 40(5):440-2. PubMed ID: 1495826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefixime and six other agents against nosocomial pathogens of the Enterobacteriaceae family.
    Mulligan ME
    Infect Control; 1987 Jun; 8(6):241-4. PubMed ID: 3498702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro evaluation of ceftibuten (7432-S, SCH 39720), a novel orally administered cephalosporin.
    Jones RN; Barry AL
    Chemioterapia; 1988 Oct; 7(5):283-6. PubMed ID: 3147148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative antimicrobial spectrum and activity of ceftibuten against clinical isolates from West Germany.
    Bauernfeind A
    Diagn Microbiol Infect Dis; 1991; 14(1):63-74. PubMed ID: 2013211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shedding of Clostridium difficile, fecal beta-lactamase activity, and gastrointestinal symptoms in 51 volunteers treated with oral cefixime.
    Chachaty E; Bourneix C; Renard S; Bonnay M; Andremont A
    Antimicrob Agents Chemother; 1993 Jul; 37(7):1432-5. PubMed ID: 8363371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefixime vs. cefaclor in the treatment of acute otitis media in infants and children.
    Kenna MA; Bluestone CD; Fall P; Stephenson J; Kurs-Lasky M; Wucher FP; Blatter MM; Reisinger KS
    Pediatr Infect Dis J; 1987 Oct; 6(10):992-6. PubMed ID: 3696840
    [No Abstract]   [Full Text] [Related]  

  • 15. [The effect of cefaclor and cefixime on nasopharyngeal pathogens in children].
    Tomiyama M
    Nihon Jibiinkoka Gakkai Kaiho; 1995 Apr; 98(4):659-68. PubMed ID: 7782974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of sinus empyema in adults. A coordinated Nordic multicenter trial of cefixime vs. cefaclor.
    Carenfelt C; Melen I; Odkvist L; Olsson O; Prellner K; Rudblad S; Savolainen S; Skaftason S; Sorri M; Synnerstad B
    Acta Otolaryngol; 1990; 110(1-2):128-35. PubMed ID: 2201163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antibacterial activity and beta-lactamase stability of SY5555, a new oral penem antibiotic.
    Inoue E; Mitsuhashi S
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1974-9. PubMed ID: 7811005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of an oral iminomethoxy aminothiazolyl cephalosporin, R-3746.
    Chin NX; Neu HC
    Antimicrob Agents Chemother; 1988 May; 32(5):671-7. PubMed ID: 3260766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative in vitro activity of cefixime, cefaclor and loracarbef against urinary pathogens.
    Hamilton-Miller JM; Brumfitt W
    Drugs Exp Clin Res; 1991; 17(10-11):517-9. PubMed ID: 1841042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMY 28100, a new oral cephalosporin.
    Leitner F; Pursiano TA; Buck RE; Tsai YH; Chisholm DR; Misiek M; Desiderio JV; Kessler RE
    Antimicrob Agents Chemother; 1987 Feb; 31(2):238-43. PubMed ID: 3105449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.